Norsk Innovasjonskapital invests in GlucoSet.
Summary
Televenture Management, through Norsk Innovasjonskapital fund, owns a little more than 50% in GlucoSet. Glucoset develops a real-time intravascular blood glucose monitoring system, reducing harmful hypoglycemia and making Intensive Insulin Therapy possible in the Intensive Care Units (ICU). The effect of all ICU patients receiving insulin is reduced mortality and significant savings in high-cost patient group.
Classifications
industries
HealthTech
applications
Computer Aided Design (CAD)
AskAI Classifications
Labels
Healthcare Software
Medical Device Software
SaaS for Healthcare Monitoring
Linked Companies
GlucoSet AS
$1M to $5M